Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2006-07-11
2006-07-11
Clardy, S. Mark (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S613000, C514S624000, C514S659000, C514S810000, C514S811000, C514S812000, C514S813000
Reexamination Certificate
active
07074833
ABSTRACT:
A method for treating or preventing a disorder or a condition by double inhibition of serotonin (5-HT) and noradrenaline (NA) reuptake in a subject in need thereof, while limiting the risks of cardiovascular disturbances and/or organ and/or tissue toxicity, comprising the step of administering to said subject a mixture of enantiomers of milnacipran enriched in the (1S,2R) enantiomer of milnacipran and/or of at least one of its metabolites, as well as their pharmaceutically-acceptable salts.
REFERENCES:
patent: 4478836 (1984-10-01), Mouzin et al.
patent: 5532244 (1996-07-01), Wong et al.
patent: 6028070 (2000-02-01), Heiligenstein
patent: 6184222 (2001-02-01), Heiligenstein
patent: 6602911 (2003-08-01), Kranzler et al.
patent: 6635675 (2003-10-01), Kranzler et al.
patent: 6699506 (2004-03-01), Paillard et al.
patent: 2002/0010216 (2002-01-01), Rogosky et al.
patent: 2003/0130353 (2003-07-01), Kranzler et al.
patent: 2003/0139476 (2003-07-01), Kranzler et al.
patent: 2003/0203055 (2003-10-01), Rao et al.
patent: 2003/0232805 (2003-12-01), Kranzler et al.
patent: 2004/0034101 (2004-02-01), Rao et al.
patent: 2004/0122104 (2004-06-01), Hirsh et al.
patent: 2005/0032782 (2005-02-01), Rao et al.
patent: 2005/0096395 (2005-05-01), Rao et al.
patent: 2759290 (1998-08-01), None
patent: 2759906 (1998-08-01), None
patent: WO09735574 (1997-10-01), None
patent: WO0126623 (2001-04-01), None
patent: WO0162236 (2001-08-01), None
patent: 03068211 (2003-08-01), None
patent: WO 04/030633 (2004-04-01), None
STN/CAS online, file CAPLUS, Acc. No. 2000:737462, Doc. No. 134:246877 (Tsuruta et al., “Examination of drug—drug interaction of milnacipran hydrochloride in the presence of human P-450”, Iyakuhin Kenkyu (2000), Vo. 31, No. 9, pp. 659-667) Abstract.
Bonnaud et al., “1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives: A new series of potential antidepressant”, J. Med. Chem. (1987), vol. 30, No. 2, pp. 318-325.
W. Retz, et al.; European Neuropsychopharmacology, vol. 5-No. 3 (1995) pp. 296-297.
Index Merck No. 6281 (1996).
Moret et al., 1985 Neuropharmacology 24(12): 1211-1219.
Bonnaud et al., 1985, Journal of Chromatography, vol. 318: 398-403.
Shuto et al., Tetrahedron letters, 1996 vol. 37: 641-644.
Grard et al.,2000, Electrophoresis 2000 21: 3028-3034.
Doyle et al., 2001, Advanced Synthesis and Catalysis, vol. 343. 299-302.
Nores et al., 1987 Therapie 42: 555, 558.
Meador-Woodruff et al., 1988 J. Clim. Psychopharmacol. 8: 28-32.
Dictionnaire Vidal, 78 eme Edition, 2002.
The Diagnostic and Statistical Manual of Mental Disorders-IV(DSM-IV), 1995 A.P.A.
Deprez et al., European Journal of Drug Metabolism & Pharmacokinetics, 1998.
Spencer et al., Drugs, 1998.
Puozzo et al., European Journal of Drug Metabolism & Pharmacokinetics, 1998.
Viazzo et al., Tetrahedron letters, 1996 vol. 37: 4519-4522.
Shuto et al., Journal of Medicinal Chemistry, vol. 41, pp. 3507-3514, (1998).
Shuto et al., Journal of Med Chem, American Chem. Society, 1996, vo. 39: 4844-4852.
Shuto et al., Japanese Journal of Pharmacology, 2001, vol. 85, p. 207-213.
Hindmarch I., Human Psychopharmacology 2001 UK, vol. 16 p. S101-S104.
Baldwin D.S., Human Psychopharmacology 2001, vol. 16, p. S93-S99.
Artigas, “Selective Serotonin/Noradrenaline Reuptake Inhibitors”,CNS Drugs, 1995, 4, 79-89.
Preskorn, et al., “Other Antidepressants”,Antidepressants: Past, Present and Future, 2004, 264-311.
Preskorn, “Milnacipran: A Dual Norepinephrine and Serotonin Reuptake pump Inhibitor”,Journal of Psychiatric Practice, 2004, 10, 119-126.
Yoshida, et al., “Elevation of blood pressure induced by high-dose milnacipran”,Hum. Psychopharmacol. Clin. Exp., 2002, 17, 431.
Schorderet, “Effects sur le système cardiovasculaire”, Pharmacologie Des Concepts Fondamentaux Aux Applications Thérapeutiques, 1992, Chapter 25, pp. 363-364.
Ener, et al., “Serotonin Syndrome and Other Serotonergic Disorders”,Pain Medicine, 2003, 4, 63-74.
Kolecki, “Isolated Venlafaxine-Induced Serotonin Syndrome”,J. Emerg. Med., 1997, 15, 491-493.
Hansen, et al., “Long-term antidepressive medication—an increased anesthetic risk?”,Der Anaesthesist, 1990, 39, 205-210 (Surgical Medline Extract).
Thase, “Effects of Venlafaxine on Blood Pressure: A Meta-Analysis of Original Data from 3744 Patients”,J. Clin. Psychiatry, 1998, 59, 502-508.
Partridge, et al., “A Depressed Myocardium”,Clinical Toxicology, 2000, 38, 453-455.
Jordan, et al., “Influence of sibutramine on blood pressure: evidence from placebo-controlled trials”,Int. J. Obes. Relat. Metab. Disord., 2005, 29, 509-516 (Medline Extract)
Birkenfeld, et al., “Paradoxical effect of sibutramine of autonomic cardiovascular regulation”,Circulation, 2002, 106, 2459-2465 (Medline Extract).
Sramek, et al., “Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, radomised trial”,J. Hum. Hypertens., 2002, 16, 13-19 (Medline Extract).
Szabadi, et al., “The human pharmacology of reboxetine”,Hum. Psychopharmacol., 1998,Suppl. 1, S3-S12 (Excerpta Medica Extract).
Middleton, et al., “Evidence that imipramine-induced postural hypotension may be centrally mediated”,Hum. Psychopharmacol., 1998, 3, 181-190 (Excerpta Medica Extract).
Robinson, “Antidepressant Psychopharmacology: Current Limitations and Future Directions”,Primary Psychiatry, 2003, 10, 43-49.
U.S. Appl. No. 10/623,431, filed Jul. 18, 2003, Kranzler et al.
U.S. Appl. No. 10/628,141, filed Jul. 24, 2003, Rao et al.
Caron, et al.,Eur. Neuropsychopharmacol, “Acute electrophysiological effects of intravenous milnacipran, a new antidepressant agent”, 1993, 3, 493-500.
Mills,Crit. Care Clin. “Serotonin Syndrome, A Clinical Update”, 1997, 13, 763-783.
Palazidou, et al., “Rapid Reference to Depression”, Jul., 2002, 42-59.
Deregnaucourt Jean
Grosse Richard
Choi Frank I.
Clardy S. Mark
Hueschen and Sage
Pierre Fabre Medicament
LandOfFree
Use of the (1S,2R) enantiomer of milnacipran for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of the (1S,2R) enantiomer of milnacipran for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of the (1S,2R) enantiomer of milnacipran for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3586165